Employer FAQs on the Rise of GLP-1 Drugs for Weight Loss and the Workplace Impact The rise of prescription medications used for weight loss has reshaped conversations about employer-sponsored health benefits and raised many new questions for employers
This ENDO 2026 study proves that doctors cannot simply assume their patients will start working out once they lose weight
This inhibition consecutively leads to post-prandial GLP-1 plasma concentrations that are elevated 2-3-fold and mediates the glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion (Table 1 gives a summary of the clinical phase III studies with at least 52 weeks duration on the efficacy of DPP-4 inhibitors compared to sulfonylureas as add on therapy to metformin, respectively, in patients not reaching their glycaemic goals with a monotherapy of metformin
How It Works: Fermentable fibers resist digestion in the small intestine and reach the colon intact
Long-term weight management
Herzberg-Schfer S, Heni M, Stefan N, Hring H-U, Fritsche A
.jpg)
